Prevention of bone marrow failure in fanconi anemia through fancm inhibition

The University of Sydney received a $239,856 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 15, 2025, with completion scheduled for July 14, 2028. The award supports research focused on prevention of bone marrow failure in Fanconi anemia through FANCM inhibition. This research initiative represents the DHA's investment in advanced biomedical research aimed at developing novel therapeutic interventions and clinical applications to address critical health challenges relevant to military personnel and the broader public health.

The research project conducted at the University of Sydney's Australian facility will investigate molecular mechanisms and potential treatment approaches to prevent bone marrow failure—a serious complication of Fanconi anemia—through targeted FANCM inhibition strategies. As a leading research institution with an established track record of federal biomedical research, the University of Sydney will deliver hypothesis-driven research findings and scientific outputs consistent with the Military Medical Research and Development program's emphasis on translational studies and therapeutic development to advance healthcare innovation.